A randomized phase II trial of interleukin-2 and interferon- α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1.

CONCLUSIONS: The addition of BEV to IL-2/IFN did not add efficacy in mRCC. (ClinicalTrials.gov, NCT01274273.).
PMID: 29392960 [PubMed - as supplied by publisher]

Source: Acta Oncologica - February 2, 2018 Category: Cancer & Oncology Authors: Donskov F, Jensen NV, Smidt-Hansen T, Brøndum L, Geertsen P Tags: Acta Oncol Source Type: research